SCHEMBL14203

SCHEMBL14203

NCCCNCc1ccc(-c2c[nH]c(NC(=O)NCCc3c(Cl)cccc3Cl)nc2=O)cc1F

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.40
ALDH2 P05091 2/20 0.40
PDCD1LG2 Q9BQ51 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
GRK5 P34947 1/20 0.34
ROCK2 O75116 2/20 0.33
ROCK1 Q13464 2/20 0.33
ABL1 P00519 1/20 0.33
MARS1 P56192 1/20 0.33
RET P07949 1/20 0.33
KDR P35968 1/20 0.33
BDKRB1 P46663 2/20 0.32
GOT1 P17174 1/20 0.32
BTK Q06187 1/20 0.32
CHEK1 O14757 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13669 0.91 CNR1 (0.45) CNR1ALDH2ROCK2ROCK1GOT1
SCHEMBL14056 0.90 CNR1 (0.42) CNR1ALDH2PDCD1LG2CD274ROCK2
SCHEMBL13618 0.90 ALDH2 (0.40) ALDH2PDCD1LG2CD274GRK5RET
SCHEMBL14022 0.89 RAF1 (0.38) ALDH2ROCK2ROCK1GOT1
SCHEMBL17354225 0.89 CNR1 (0.36) CNR1ALDH2PDCD1LG2CD274ROCK2
SCHEMBL14850227 0.89 CNR1 (0.41) CNR1ROCK2ROCK1
SCHEMBL13571 0.87 ALDH2 (0.39) ALDH2PDCD1LG2CD274GRK5ABL1
SCHEMBL14067 0.87 ALDH2 (0.39) ALDH2PDCD1LG2CD274GRK5ABL1
SCHEMBL14149 0.87 ROCK2 (0.40) CNR1ALDH2ROCK2ROCK1BDKRB1
SCHEMBL13702 0.87 CA2 (0.38) CNR1ROCK2ROCK1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9845297-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-12-19 US disclosed
US-9845297-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-12-19 US disclosed
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2016-02-04 US disclosed
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2016-02-04 US disclosed
US-9216979-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-12-22 US disclosed
US-9216979-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-12-22 US disclosed
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
WO-2011047323-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT CNR1 4516/4885ALDH2 611/4885PDCD1LG2 3978/4885
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT CNR1 4516/4885ALDH2 611/4885PDCD1LG2 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.